Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group).

@article{Muss1985TreatmentOR,
  title={Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group).},
  author={Hyman Bernard Muss and Brian N. Bundy and Philip John Disaia and Howard D. Homesley and Wesley C Fowler and W Creasman and Edgardo Yordan},
  journal={Cancer},
  year={1985},
  volume={55 8},
  pages={1648-53}
}
Recurrent or metastatic uterine sarcoma represents an ominous and aggressive form of malignant disease. In an attempt to define a beneficial treatment program, we compared treatment with doxorubicin (A) 60 mg/m2 versus a combination of doxorubicin 60 mg/m2 and cyclophosphamide 500 mg/m (CA), each regimen given every 3 weeks. Of 132 patients entered on study, 104 were eligible; 50 received A and 54 CA. Pretreatment characteristics were similar, and no patient had received prior chemotherapy. The… CONTINUE READING
51 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 51 extracted citations

Similar Papers

Loading similar papers…